Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Saharman Y.R., Karuniawati A., Severin J.A., Verbrugh H.A.
55980934300;54886816200;8700385500;7103296623;
Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review
2021
Antimicrobial Resistance and Infection Control
10
1
22
4
Department of Clinical Microbiology, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, Netherlands
Saharman, Y.R., Department of Clinical Microbiology, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, Netherlands; Karuniawati, A., Department of Clinical Microbiology, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Severin, J.A., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, Netherlands; Verbrugh, H.A., Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam, 3015 GD, Netherlands
Background: Intensive care units (ICUs) in lower-middle income countries (LMICs) are suspected to constitute a special risk for patients of acquiring infection due to multiple antibiotic resistant organisms. The aim of this systematic scoping review was to present the data published on ICU-acquired infections and on antimicrobial resistance observed in ICUs in LMICs over a 13-year period. A systematic scoping review was conducted according to the PRISMA extension guideline for scoping reviews and registered in the Open Science Framework. Main body of the abstract: Articles were sought that reported on ICU-acquired infection in LMICs between 2005 and 2018. Two reviewers parallelly reviewed 1961 titles and abstracts retrieved from five data banks, found 274 eligible and finally included 51. Most LMICs had not produced reports in Q1 or Q2 journals in this period, constituting a large gap in knowledge. However, from the reported evidence it is clear that the rate of ICU-acquired infections was comparable, albeit approximately 10% higher, in LMICs compared to high income countries. In contrast, ICU mortality was much higher in LMICs (33.6%) than in high income countries (< 20%). Multidrug-resistant Gram-negative species, especially Acinetobacter baumannii and Pseudomonas aeruginosa, and Klebsiella pneumoniae played a much more dominant role in LMIC ICUs than in those in high income countries. However, interventions to improve this situation have been shown to be feasible and effective, even cost-effective. Conclusions: Compared to high income countries the burden of ICU-acquired infection is higher in LMICs, as is the level of antimicrobial resistance; the pathogen distribution is also different. However, there is evidence that interventions are feasible and may be quite effective in these settings. Protocol Registration The protocol was registered with Open Science Framework (https://osf.io/c8vjk) © 2021, The Author(s).
Acinetobacter; Bacterial drug resistance; Cross infection; Infection control; Intensive care units
antibiotic agent; Acinetobacter baumannii; adult; antibiotic resistance; bacterial infection; cross infection; female; high income country; hospital mortality; human; infection control; intensive care unit; Klebsiella pneumoniae; major clinical study; male; middle income country; multidrug resistance; nonhuman; priority journal; Pseudomonas aeruginosa; Review; bacterial infection; cross infection; developing country; Acinetobacter baumannii; Adult; Bacterial Infections; Cross Infection; Developing Countries; Drug Resistance, Bacterial; Humans; Intensive Care Units; Klebsiella pneumoniae; Pseudomonas aeruginosa
BioMed Central Ltd
20472994
33514432
Review
Q1
1456
2381